Lung cancer costs by treatment strategy and phase of care among patients enrolled in Medicare

Abstract

Cost-effectiveness analyses of lung cancer control interventions in the United States have been using outdated and incomplete treatment cost estimates. Our cost estimates enable updated cost-effectiveness analyses to determine the benefit of lung cancer control from a health economics point of view.